Doxycycline 100mg, 10 Capsules — TM Darnytsia

Doxycycline ™ "Darnitsa" — 10 Capsules (1 Blister)

This product listing features a complete pack containing 10 capsules of Doxycycline (100 mg each) manufactured by the leading Ukrainian pharmaceutical company Darnitsa. This standardized format is highly optimized for precise short-cycle tracking, pulsed schedules, or customized evaluations within advanced off-label oncology prevention and cellular longevity research frameworks.

General Pharmaceutical & Manufacturer Information

• Brand Name: Doxycycline-Darnitsa (Доксициклін-Дарниця)
• Active Ingredient: Doxycycline (as Doxycycline hyclate)
• Dosage: 100 mg of Doxycycline per capsule
• Package Size: 1 Blister (10 capsules)
• CAS Number: 24390-14-5 (Doxycycline hyclate)
• Molecular Formula: C22H24N2O8·HCl·0.5H2O·0.5C2H6O
• Form: Hard oral capsules
• Manufacturer: Pharmaceutical Company "Darnitsa" (PrAT "Darnitsa"), Kyiv, Ukraine
• Manufacturer Profile: Founded in 1930, Darnitsa is the largest manufacturer of affordable medicines in Ukraine, operating under stringent international Good Manufacturing Practice (GMP) certifications to ensure premium baseline purity, precise chemical consistency, and strict quality control.

Primary Therapeutic Focus: Oncology Prevention & Management (Off-Label Context)

Beyond its classic classification as a broad-spectrum antibiotic, Doxycycline is heavily prioritized in cutting-edge translational oncology as a core metabolic disruptor. Research utilizing the 100 mg dose structure focuses on specific biochemical pathways to target tumor cell vulnerability and block disease progression:

• Selective Inhibition of Cancer Stem Cells (CSCs): Cancer stem cells represent the most resilient subpopulation within tumors, acting as the primary drivers of treatment resistance, recurrence, and metastatic seeding. Doxycycline selectively neutralizes CSCs by targeting and inhibiting mitochondrial biogenesis. Because mammalian mitochondria share evolutionary prokaryotic origins, the compound selectively limits mitochondrial protein translation, effectively stripping the stem cells of their survival and self-renewal capacities.
• Suppression of Matrix Metalloproteinases (MMPs): Doxycycline functions as a highly potent inhibitor of matrix metalloproteinases, specifically MMP-2 and MMP-9. In a preventive or adjuvant oncological context, downregulating MMP activity prevents the degradation of the surrounding extracellular matrix. This systematically restricts tumor cell invasion, migration, and the structural development of tumor angiogenesis (the formation of new blood vessels that feed malignant lesions).
• Disruption of Tumor Microenvironmental Symbiosis: Doxycycline interrupts the critical metabolic cross-talk and energy signaling between local stromal structures and pre-cancerous cells, cutting off the specialized microenvironmental energy supply necessary for rapid cell survival.

Anti-Aging & Longevity Properties (Geroprotection)

In addition to its anti-tumor mechanisms, low-dose or intermittent Doxycycline administration addresses foundational hallmarks of systemic biological aging:

• Mitigation of Chronic Inflammaging: The compound downregulates primary pro-inflammatory cytokines—including TNF-α and IL-6—and actively inhibits the NF-κB signaling cascade. This directly counters inflammaging, the persistent, low-grade systemic inflammation that drives progressive tissue degeneration.
• Mitochondrial and Stress Adaptation: Preclinical models suggest that low-dose exposure can modulate internal oxidative stress markers, optimizing baseline mitochondrial structural resilience against metabolic insults.
• Neuroprotective Action: Experimental data demonstrate a clear capacity to reduce neuroinflammation and chemically limit the formation of toxic protein aggregates, making it a valuable target in Alzheimer's and Parkinson's disease models.

Administration & Strict Disclaimer

In advanced research and off-label protocols, a 10-capsule format serves as an ideal volume for targeted pulse-dosing cycles or intermittent combination strategies designed to minimize systemic adaptation while maintaining localized metabolic stress on malignant cells.

Strict Regulatory Disclaimer: This product is presented for laboratory research, evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.